The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of circulating tumor cells (CTCs) to clinically assess multiple myeloma and its precursors. Dr Ghobrial highlights the value of whole genome sequencing and single-cell RNA sequencing of CTCs to understand the genomic features of patients and predict progression. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we are excited to say that yes we can do bone marrow biopsies but bone marrow biopsies are painful and we don’t do them as often. So can we use circulating tumor cells not only to count them because they are important prognostically but also to look at them by whole genome sequencing or by single cell RNA sequencing to really use them to identify patients who will progress or who will not progress, but to also understand the genomic features of those patients...
So we are excited to say that yes we can do bone marrow biopsies but bone marrow biopsies are painful and we don’t do them as often. So can we use circulating tumor cells not only to count them because they are important prognostically but also to look at them by whole genome sequencing or by single cell RNA sequencing to really use them to identify patients who will progress or who will not progress, but to also understand the genomic features of those patients. Because we know that numbers alone are not enough, we need to understand who’s truly high-risk and who’s not. And we can redefine smoldering myeloma by saying who is high-risk genomically, and we need to treat them in a different way than those who are not high-risk genomically.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen: Consultancy, Other: Speaker fees; GlaxoSmithKline: Consultancy; Standard Biotools: Other: Speaker fees; Aptitude Health: Consultancy; Pfizer: Consultancy, Other: Speaker fees; Takeda: Consultancy, Other: Speaker fees; Binding Site, part of Thermo Fisher Scientific: Consultancy; CurioScience: Consultancy, Other: Speaker fees; Huron Consulting: Consultancy; Janssen: Consultancy, Other: Speaker fees; Window Therapeutics: Consultancy; Menarini Silicon Biosystems: Consultancy, Other: Speaker fees; Bristol Myers Squibb: Consultancy, Other: Speaker fees; Adaptive: Consultancy; AbbVie: Consultancy; Vor Biopharma: Other: Speaker fees; Oncopeptides: Consultancy; Novartis: Consultancy; Sanofi: Consultancy; 10X Genomics: Consultancy; Regeneron: Consultancy, Other: Speaker fees; PreDICTA Bioscience: Consultancy, Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees, Other: Co-founder; Disc Medicine: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees.
